Atsushi Nohara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3634229/publications.pdf

Version: 2024-02-01

31	1,347	361388	477281
papers	citations	20 h-index	29 g-index

31	31	31	1196
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. Journal of Atherosclerosis and Thrombosis, 2022, 29, 816-824.	2.0	20
2	Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia. Atherosclerosis, 2022, 340, 28-34.	0.8	6
3	Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia. Frontiers in Genetics, 2022, 13, 872056.	2.3	8
4	Homozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 665-678.	2.0	55
5	Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. Journal of Clinical Lipidology, 2021, 15, 358-365.	1.5	23
6	Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia. Circulation Journal, 2021, 85, 2073-2078.	1.6	24
7	A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 346-351.e9.	1.5	20
8	Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype. Circulation Journal, 2019, 83, 1917-1924.	1.6	55
9	Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. Journal of Atherosclerosis and Thrombosis, 2019, 26, 368-377.	2.0	27
10	High frequency of type 2 diabetes and impaired glucose tolerance in Japanese subjects with the angiopoietin-like protein 8 R59W variant. Journal of Clinical Lipidology, 2018, 12, 331-337.	1.5	16
11	Guidance for Pediatric Familial Hypercholesterolemia 2017. Journal of Atherosclerosis and Thrombosis, 2018, 25, 539-553.	2.0	68
12	Molecular and functional characterization of familial chylomicronemia syndrome. Atherosclerosis, 2018, 269, 272-278.	0.8	16
13	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. Journal of Clinical Lipidology, 2018, 12, 1436-1444.	1.5	81
14	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2018, 25, 783-789.	2.0	90
15	Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. Journal of Atherosclerosis and Thrombosis, 2018, 25, 751-770.	2.0	171
16	sLR11 as a novel predictor of vascular calcification. Atherosclerosis, 2017, 265, 242-243.	0.8	0
17	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. European Heart Journal, 2017, 38, 1573-1579.	2.2	132
18	Recent advances in the understanding and management of familial hypercholesterolemia. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 2625-2637.	0.0	0

#	Article	IF	Citations
19	A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing. Clinica Chimica Acta, 2016, 453, 194-196.	1.1	9
20	Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method. Practical Laboratory Medicine, 2015, 1, 22-27.	1.3	5
21	Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography. American Journal of Cardiology, 2015, 115, 724-729.	1.6	60
22	Clinical characteristics of Japanese patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2015, 9, 519-524.	1.5	29
23	Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene. Atherosclerosis, 2015, 240, 324-329.	0.8	16
24	Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors. Molecules and Cells, 2014, 37, 777-784.	2.6	46
25	Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis, 2014, 236, 54-61.	0.8	78
26	Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011, 214, 404-407.	0.8	99
27	The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis, 2010, 210, 166-172.	0.8	62
28	A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: Application of the CD3/CD28 assay in lymphocytes. Clinica Chimica Acta, 2009, 400, 42-47.	1.1	21
29	High Frequency of a Retinoid X Receptor Î³ Gene Variant in Familial Combined Hyperlipidemia That Associates With Atherogenic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 923-928.	2.4	23
30	Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis, 2002, 165, 335-342.	0.8	64
31	Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia. Lancet, The, 1995, 345, 1438.	13.7	23